Background: Drug resistance mechanisms can reduce response rate and duration in men with castration-resistant prostate cancer (CRPC) receiving docetaxel-based therapy. Patupilone (epothilone B), a microtubule-targeting agent, may be unaffected by some resistance mechanisms. Therefore, a phase II study assessed the patupilone safety and activity in CRPC patients with and without previous chemotherapy.
introduction
Options for patients with castration-resistant prostate cancer (CRPC) currently include various chemotherapy regimens. Agents such as estramustine, vinblastine, mitoxantrone, and the taxanes have been evaluated in the treatment of CRPC. Large randomized studies have evaluated mitoxantrone with steroids, docetaxel with prednisone, and docetaxel plus estramustine in CRPC, with every 3-week administration of mitoxantrone/ steroids and docetaxel/prednisone approved for the treatment of metastatic CRPC [1] [2] [3] [4] [5] . However, the median duration of response remains at no more than 6 months, and overall survival (OS) is 12-18 months in such patients [1] [2] [3] [4] .
In prostate cancer, agents that appear to be particularly active target the nuclear matrix and microtubules [6] . Taxanes, which bind to and stabilize microtubules, are among the most widely used antitumor agents. Paclitaxel and docetaxel as single agents with a weekly schedule have shown a prostate-specific antigen (PSA) decline of 50% or greater in 39%-46% of patients [7, 8] . Unfortunately, peripheral neuropathy and myelosuppression may be dose-limiting toxic effects with taxanes [6] . Furthermore, studies have demonstrated that resistance to taxanes can occur through multidrug resistance mechanisms, tubulin mutations, and certain p53 mutations [9] [10] [11] .
There is a need for new agents that target microtubules but have improved safety profiles and are not substrates for multidrug resistance mechanisms. Patupilone (epothilone B; Novartis Pharmaceuticals Corporation, East Hanover, NJ) is a microtubule-targeting agent that binds to the same region of tubulin as taxanes, stabilizing the microtubules; however, the epothilones and taxanes engage the tubulin-binding pocket uniquely [12, 13] . Furthermore, patupilone stabilizes tubulin polymerization at much lower concentrations compared with paclitaxel and may bypass p53-mediated drug resistance [14, 15] . Patupilone, unlike paclitaxel, is not a substrate for P-glycoprotein and has demonstrated activity in multidrugresistant human tumor models [14] . Moreover, certain b-tubulin mutants that are resistant to taxanes are not resistant to epothilones [12, 16] . In phase I trials, patupilone has been generally safe and well tolerated, with patients experiencing no severe neuropathy or hematologic toxicity [17, 18] . Therefore, the safety and efficacy of weekly patupilone 2.5 mg/m 2 were investigated in patients with CRPC in a multicenter phase II trial.
patients and methods patients
In an effort to determine the potential safety and activity of patupilone in CRPC, a somewhat unusual aspect of the study was that it allowed inclusion of patients with CRPC with or without documented metastasis who were chemotherapy naive or who had received a prior chemotherapy regimen (excluding an epothilone). Eligible patients were at least 18 years of age, had histologically confirmed CRPC, and had evidence of progressive disease on the basis of measurable metastatic disease or PSA increases. For patients with measurable disease, changes in the size of lymph nodes or parenchymal masses on physical or radiologic examination were required. Bone scan findings alone were not adequate to assess measurable disease for study entry. For patients with disease progression defined solely by PSA increase, two consecutive increases in serum PSA levels documented at least 2 weeks apart were required, the last PSA measurement had to be at least 50% higher than the nadir PSA achieved after the last therapeutic regimen, and the PSA had to be 20 ng/ml or higher at trial entry. Patients were required to have normal hematologic function, including white blood cells >3.0 · 10 9 cells/l, absolute neutrophil count >1.5 · 10 9 cells/l, hemoglobin >9.0 g/dl, platelets >100 · 10 9 /l, and normal hepatic function. Patients were maintained on androgen ablation therapy with a luteinizing hormone-releasing hormone agonist or they had undergone an orchiectomy. If patients were on antiandrogens, they had to experience progression after antiandrogen withdrawal. Patients who had peripheral neuropathy or unresolved diarrhea higher than grade 1; who received corticosteroids, radiation therapy, or chemotherapy within 4 weeks of study entry; or who had an active infection were not eligible. Each center received Institutional Review Board approval, and all patients provided written informed consent.
study design and treatment
This was a phase II, open-label, single-arm, two-stage, multicenter study that investigated the safety and efficacy of patupilone in patients with CRPC. Patients with measurable disease were evaluated for response by the Response Evaluation Criteria in Solid Tumors (RECIST). Patients without measurable disease were evaluated by PSA criteria (see below). If at least one patient in the first stage of the study achieved a response to treatment (by RECIST or PSA response), then additional patients would be enrolled in the second stage. Patients received patupilone 2.5 mg/m 2 via 5-min bolus i.v. infusion once per week for 3 weeks, followed by 1 week of rest (4-week cycle). Patients who experienced grade 3 or higher nonhematologic toxicity (excluding nausea and vomiting controlled by antiemetics), hematologic toxicity, neurotoxicity, grade 2 or higher cardiac toxicity, or serum creatinine 2.0 · upper limits normal or greater during a treatment course had their next scheduled dose of patupilone withheld until recovery to at least grade 1 (grade 2 for diarrhea, nausea, vomiting, or mucositis). After recovery, patients were allowed to receive patupilone at a reduced dose of 2.0 mg/m 2 ; the dose could be further reduced to 1.6 mg/m 2 , if toxicity recurred.
patient assessments safety and tolerability. Adverse events were monitored and graded based on the National Cancer Institute-CommonToxicity Criteria Version 2. Hematology, blood chemistry, and vital signs were evaluated at screening, weekly before each dose, on day 1 of week 4 during cycles 1 and 2, on day 1 of the first and third weeks of each cycle before treatment for cycles 3 and over, and at the end of the study or day of discontinuation. Urine chemistry was carried out at screening and at the end of the study or day of discontinuation. World Health Organization performance status (PS) was obtained at screening, on day 1 of each cycle and at the end of the study or day of discontinuation.
antitumor activity. The primary end points were to determine the PSA response proportion for the enrolled patients and objective response in those with measurable disease. Measurable disease was evaluated by the size of the soft tissue lesions on physical examination or radiologic assessment (chest X-ray, computed tomography of the abdomen and pelvis) according to RECIST. If a tumor was found at screening by imaging studies, these radiologic assessments were repeated at each tumor evaluation. Tumor evaluations were carried out every even-numbered cycle. For patients with measurable disease, a complete response (CR) was defined as the resolution of all measurable lesions and stability on bone scan. Partial response (PR) was defined as at least a 30% decrease in the sum of the longest dimensions of the target lesions, stability on bone scan, and no decrease in PS. Progressive disease (PD) was defined as one of the following: the appearance of a new lesion on computed tomography (CT) scan, X-ray, or bone scan, at least a 20% increase in the sum of the longest dimensions of target lesions (regardless of PSA response), a decrease in PS, or the need for radiotherapy or other antitumor therapy for metastases. Patients not meeting the criteria for CR, PR, or PD were considered to have stable disease (SD).
Patients with nonmeasurable disease (including those with positive bone scans) were evaluated by PSA response. Response by PSA criteria was defined as a 50% or greater decrease in PSA level from baseline that was maintained for at least 28 days with the appearance of no new lesions on imaging studies (including bone scan) and no decrease in PS. Progression by PSA criteria was defined as a 50% or greater increase in PSA from baseline for two consecutive measurements (if treatment resulted in a PSA decline, then a 50% increase with respect to the PSA nadir was considered PD). For patients with a positive bone scan, increased intensity of radionuclide uptake in the bone by itself was not considered progressive disease unless it was associated with an increase in PSA, new lesion on X-ray or CT scan, or need for palliative radiotherapy.
Secondary end points included time to progression (defined as the start of treatment to documented disease progression), OS (measured from the first treatment dose to the date of death or the last date the patient was known to be alive), and duration of overall response (measured from the time that the first response criteria were met until recurrent disease or PD was documented).
statistical measurements
This study was on the basis of a hybrid two-stage design with an accrual goal of 18 patients in the first stage and 22 patients in the second stage. Patients were to be enrolled in the second stage if a signal of antitumor activity (PSA response or objective response) was seen in at least one of the first 18 patients enrolled in the first stage of the trial. The sample sizes were chosen to differentiate a null (H o ) and alternative (H 1 ) hypothesis-H o : P £0.05 versus H 1 : P ‡0.20 with a type I error rate of 0.05 and power equal to 90%, where P is the true response rate.
Descriptive statistics were used to summarize demographic and baseline disease characteristics and the total dose of patupilone by cycle. The safety population included all patients who received one or more dose of patupilone. The efficacy population consisted of all patients for whom response data were available when the last patient completed a maximum of six cycles. Summary statistics were used to present adverse event and response data. Time to progression and OS were estimated using Kaplan-Meier analysis.
results patient characteristics and disposition
Forty-five patients with a median age of 69 years (range 52-84 years) were enrolled in this study (Table 1) . Men <65 years of Annals of Oncology original article age comprised only 38% of the patient population. Only one (2%) patient had a PS of two, and one (2%) patient's PS was unknown. The majority (73%) of patients were at least 3 years beyond their initial diagnosis. Sixty-four percent of patients had received previous chemotherapy: 19 (42%) patients had received one, eight (18%) patients had received two, and two (4%) patients had received more than two previous chemotherapy regimens. Twenty-five (55%) patients had received prior taxanes. Eleven patients had bone metastases only, and nine patients had bone metastases and other measurable metastatic disease. Ten patients had measurable metastatic disease without bone metastases, and 12 patients had increasing PSA only without metastatic disease. Patients received a median of three cycles (range 1-15 cycles) of patupilone, and the median of total doses was 7 (range 2-30). All 45 patients were assessable for safety and response.
safety assessments non-hematologic toxicity. The most common adverse events were diarrhea, fatigue, nausea, and vomiting (Table 2) . Except for one1 patient with grade 4 abdominal pain, no other grade 4 gastrointestinal adverse events were reported. Ten (22%) patients experienced grade 3 diarrhea, but only two discontinued treatment because of this event. Grade 2 diarrhea was reported in eight (18%) patients, and grade 1 diarrhea was reported in 17 (38%) patients. Diarrhea was managed with dose adjustments in eight patients, loperamide in 26 patients, and octreotide in three patients. The median time to diarrhea was 15 days. The median duration of grade 3 diarrhea was 14 days, and the median duration of grade 1/2 diarrhea was 2 days or less. There were no patient discontinuations because of other gastrointestinal adverse events. Five (11%) patients had grade 3 nausea and vomiting. Dose adjustments were implemented for two (4%) patients each because of nausea and vomiting.
Except for fatigue, the incidence of other nongastrointestinal adverse events was low. Six (13%) patients reported grade 3 fatigue. Three (7%) patients had dose adjustments because of fatigue, but no patients discontinued treatment because of this adverse event. No grade 4 neurologic adverse events were reported, and only one (2%) patient had grade 3 neuropathy and discontinued treatment. Two (4%) patients had grade 2 peripheral neuropathy, and 14 (31%) patients had grade 1. Treatment was discontinued for only two patients because of peripheral neuropathy. Other neurologic dysfunctions such as dysgeusia, hypoesthesia, and dizziness were also uncommon, with no grade 3/4 toxicity, grade 2 toxicity in <5% of patients, and grade 1 toxicity in 11%-24% of patients. Only one (2%) patient had grade 1 alopecia. hematologic toxicity. Anemia was the most common hematologic event, with 11 (24%) patients reporting grade 1/2 anemia ( Table 2) . One (2%) patient experienced grade 3 (Table 4) . Of the 19 patients who had received one previous chemotherapy regimen, two (11%) had a PSA response, and of the eight patients who had received two previous regimens, one (13%) had a PSA response. It is interesting that all three of these patients who achieved PSA response had received previous taxane therapy. None of the patients with measurable disease had a response by RECIST criteria (Table 3 ). The median duration of response had not been reached at the final study evaluation. Kaplan-Meier estimates of the time to progression are shown in Figure 1 . The median time to progression was 1.6 months [95% confidence interval (CI) = 1.4, 1.9 months]. The median OS for chemotherapy-naive and chemotherapy-treated patients was essentially identical; for the entire enrolled population, it was 13.4 months (95% CI = 10.7, 16.5 months).
discussion
The microtubular network represents an important target in the treatment of advanced prostate cancer, as demonstrated by two large randomized clinical trials that showed a survival advantage with docetaxel-based therapy in patients with metastatic CRPC [3, 4] . However, the survival benefit of docetaxel-based therapy is of limited duration, and metastatic CRPC remains an incurable disease. Nevertheless, given the activity of taxanes in prostate cancer, a concerted effort is being made to identify other microtubule-targeting agents that may have greater antitumor activity in this disease. Epothilones have emerged as a potentially important class of drugs, and trials with some of the epothilones are being piloted to determine whether more effective treatment regimens for prostate cancer can be identified and developed. Different treatment schedules of these drugs are being tested, including weekly, every 3 weeks, daily three times every 3 weeks, or daily five times every 3 weeks [19] . We now report the results of a naturally occurring epothilone B, patupilone, given weekly for 3 out of a 4-week cycle.
In this study, patupilone was safe and well tolerated, with a low incidence (2%) of grade 3 neuropathy and no observed myelosuppression. This overall safety profile compares favorably with the safety profile of taxanes. For example, with weekly paclitaxel, grade 3 peripheral neuropathy has been previously reported in up to 35% of patients, compared with 2% of patients in this study [7] . However, paclitaxel is not considered standard of care in patients with prostate cancer. Moreover, grade 3/4 hematologic toxicity has been reported in up to 21% of patients with advanced CRPC receiving weekly docetaxel (a taxoid), although, in general, less myelosuppression is noted with weekly taxane regimens compared with every 3-week regimens in patients with CRPC [6, 20] . By contrast, with the patupilone dose and schedule used in this study, there were no adverse event reports of neutropenia or thrombocytopenia. CRPC, castration-resistant prostate cancer. Table 4 . PSA response proportion in CRPC patients receiving patupilone
All patients, n (%) (n = 45)
Patients with nonmeasurable disease, n (%) (n = 26)
PSA response 6 (13) 6 (23) CRPC, castration-resistant prostate cancer; PSA, prostate-specific antigen. 
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Recently, two phase II trials with the semisynthetic epothilone B ixabepilone given every 3 weeks have been reported in patients with metastatic chemotherapy-naive CRPC [21, 22] . In the randomized study by Galsky et al., grade 3/4 neuropathy was seen in 13% of the patients in the ixabepilonealone arm and in 7% of the patients in the ixabepilone plus estramustine arm, whereas in the Southwest Oncology Group (SWOG) trial, a 19% incidence of grade 3 neuropathy was observed [21, 22] . In contrast to results seen with the weekly patupilone regimen, myelosuppression was also more prominent in the ixabepilone studies: grade 3/4 neutropenia occurred in 22% (ixabepilone) and 29% (ixabepilone plus estramustine) of patients in the randomized study; grade 3 hematologic toxicity and grade 4 neutropenia/leukopenia were reported in 17% and 7% of patients, respectively, in the SWOG study [21, 22] . In an effort to decrease some of the toxic effects seen with ixabepilone administered every 3 weeks, the Eastern Cooperative Oncology Group is conducting a pilot study of weekly ixabepilone with a lower dose in metastatic CRPC [23] . Similar to results in the current study, a relatively small proportion of patients experienced grade 3 fatigue with ixabepilone (9%), and neither patupilone nor ixabepilone was highly emetogenic in the prostate cancer patients [21, 22] .
Diarrhea, the dose-limiting toxicity in early patupilone phase I studies, was generally manageable with loperamide in this study, and no patients experienced grade 4 diarrhea. Although diarrhea was observed in the majority of patients (35 of 45), it generally occurred during the initial stages of patupilone administration; of the 10 (22%) patients who experienced grade 3 diarrhea, nine patients reported diarrhea in the first cycle, and only one patient reported diarrhea in the second cycle. Further episodes of grade 3/4 diarrhea did not occur in subsequent cycles, likely reflecting the efficacy of antidiarrhea management in these patients. Of note, the median duration of grade 1/2 diarrhea was significantly less than that for grade 3 diarrhea (<2 days versus 14 days).
Among the 45 treated patients, six (13%) achieved a response by PSA criteria, while no patient with measurable disease had an objective response. At the final study evaluation, the median duration of PSA response had not yet been reached but was >3 months. A point of note regarding this trial is that, although the enrolled patients had CRPC, the treated population was heterogeneous with respect to disease status and exposure to prior chemotherapy. Presence of metastatic disease was not a requirement for trial entry, and in fact 12 (27%) patients had PSA-only disease. Additionally, 29 (64%) patients had received previous chemotherapy, and among the six patients achieving PSA response, three had received prior taxane-based chemotherapy. Thus, although true response rates with weekly patupilone in the different subpopulations of CRPC are difficult to ascertain from the present trial given the limited number of patients in the various cohorts, it is apparent from this study that, overall, weekly patupilone at best has limited activity in CRPC. Higher response rates were seen in both ixabepilone trials compared with response rates observed in our study, with PSA response of 33%-48% and objective response of 15%-32% in ixabepilone-treated patients [21, 22] . However, in contrast to patients in the patupilone study, all enrolled patients in the two ixabepilone trials were chemotherapy naive.
The response rates with ixabepilone are not too dissimilar from the responses observed with docetaxel administered every 3 weeks to patients with metastatic CRPC in the first-line setting. A 17% PSA response rate has been reported with ixabepilone when given as second-line therapy by Rosenberg et al. [24] in a well-defined population of patients with CRPC; all patients in this trial had metastatic CRPC and had progressed during or within 60 days of receiving taxane-based chemotherapy. Thus, the epothilones do appear to have some, but limited, activity in taxane-treated patients.
Given the modest response rates observed, further development of patupilone in advanced prostate cancer at the dose and schedule tested is not warranted. Rather, the dose and schedule of patupilone administration need to be further optimized to improve antitumor activity while minimizing adverse effects. A once every 3 weeks schedule with proactive antidiarrhea management appears to be the most promising schedule, with a further reduction in diarrhea and fatigue compared with the results presented here [25, 26] . A recently launched randomized phase II study is comparing patupilone (10 mg/m 2 ) every 3 weeks with docetaxel (75 mg/m 2 ) every 3 weeks in patients with metastatic chemotherapy-naive CRPC, and another epothilone, ZK-EPO, is undergoing initial testing in prostate cancer. Whether any of the epothilones will find a role in the management of prostate cancer is not yet fully resolved [27] . Results of the trial with patupilone administered every 3 weeks to patients with CRPC are awaited. 
